Disorders in cell circuitry associated with multistage carcinogenesis: Exploitable targets for cancer prevention and therapy

Clinical Cancer Research

Volumn 3, Issue 12 II, 1997, Pages 2696-2702

  Weinstein, I Bernard ^a   Begemann, Martin ^a   Zhou, Ping ^a   Han, Edward K H ^a   Sgambato, Alessandro ^a   Doki, Yuichiro ^a   Arber, Nadir ^a   Ciaparrone, Marco ^a   Yamamoto, Hirofumi ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; CALPHOSTIN C; COMPLEMENTARY DNA; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN E; INHIBITOR PROTEIN; MIDOSTAURIN; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR;

CANCER INHIBITION; CANCER PREVENTION; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE; CONFERENCE PAPER; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

APOPTOSIS; CELL CYCLE; CHEMOPREVENTION; CYCLIN D1; DRUG DESIGN; GENE THERAPY; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 0031417677     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Weinstein, I. B., Carothers, A. M., Santella, R. M., and Perera, F. P. Molecular mechanisms of mutagenesis and multistage carcinogenesis. In: J. Mendelsohn, P. M. Howley, M. A. Israel, and L. A. Liotta (eds.). The Molecular Basis of Cancer, pp. 59-85. Philadelphia: W. B. Saunders Co., 1995.
2. Weinstein, I. B. Relevance of cyclin D1 and other molecular markers to cancer chemoprevention. J. Cell. Biochem., 25S: 23-28, 1996.
3. Weinstein, I. B., Borner, C. M., Krauss, R. S., O'Driscoll, K., Choi, P. M., Morotomi, M., Hoshina, S., Hsieh, L-L., Tchou-Wong, K-M., Guadagno Nichols, S., Ueffing, M., and Guillem, J. G. Pleiotropic effects of protein kinase C and the concept of carcinogenesis as a progressive disorder in signal transduction. In: J. Brugee (ed.). Origins of Human Cancer: A Comprehensive Review, pp. 113-124. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1991.
4. Cacace, A., Ueffing, M., Philipp, A., Han, E. K-H., Kolch, W., and Weinstein, I. B. PKC epsilon functions as an oncogene by enhancing activation of the RAF kinase. Oncogene, 13: 2517-2526, 1996.
5. Begemann, M., Kashimawo, S. A., Choi, Y-J., Kim, S., Christiansen, K. M., Duigou, G., Mueller, M., Schieren, I., Ghosh, S., Fabbro, D., Lampen, N. M., Schiff, P. B., Bruce, J. N., and Weinstein, I. B. Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter. Clin. Cancer Res., 2: 1017-1030, 1996.
6. Hunter, T., and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
7. Sherr, C. J. Mammalian G1 cyclins. Cell, 79: 551-555, 1994.
8. Weinstein, I. B., and Zhou, P. Cell cycle control gene defects and human cancer. In: J. R. Bertino (ed.). Encyclopedia of Cancer, Vol. 1, pp. 256-267. New York: Academic Press, 1996.
9. Jiang, W., Zhang, Y-J., Kahn, S. M., Hollstein, M. C., Santella, R. M., Lu, S-H., Harris, C. C., Montesano, R., and Weinstein, I. B. Altered expression of cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc. Natl. Acad. Sci. USA, 90: 9026-9030, 1993.
10. Gillett, C., Fantl, V., Smith, R., Fisher, C., Bartek, J., Dickson, C., Barnes, D., and Peters, G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res., 54: 1812-1817, 1994.
11. Bartkova, J., Lukas, J., Strauss, M., and Bartek, J. The READ-1/ cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int. J. Cancer, 58: 568-573, 1994.
12. Arber, N., Hibshoosh, H., Moss, S. F., Sutter, T., Zhang, Y., Begg, M., Wang, S., Weinstein, I. B., and Holt, P. Increased expression of cyclin D1 in an early event in multistage colorectal carcinogenesis. Gastroenterology, 110: 669-676, 1996.
13. Arber, N., Lightdale, C., Rotterdam, H., Finegold, J., Ahsan, H., Han, E. K-H., Sgambato, A., Stevens, P. D., Green, P. H. R., Neugut, A. I., and Weinstein, I. B. Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol. Biomark. Prev., 3: 457-459, 1996.
14. Zhang, T., Nanney, L. B., Luongo, C., Lamps, L., Heppner, K. J., DuBois, R. N., and Beauchamp, R. D. Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (cdk4) in intestinal adenomas from multiple intestinal neoplasia (min) and human familial adenomatous polyposis patients. Cancer Res., 57: 169-175, 1997.
15. Naitoh, H., Shibata, J., Kawaguchi, A., Kodama, M., and Hattori, T. Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am. J. Pathol., 146: 1161-1169, 1995.
16. Shinozaki, H., Ozawa, S., Ando, N., Tsuruta, H., Terada, M., Ueda, M., and Kitajima, M. Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin. Cancer Res., 2: 1155-1161, 1996.
17. Gansauge, S., Gansauge, F., Ramadani, M., Stobbe, H., Rau, B., Harada, N., and Beger, H. G. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res., 57: 1634-1637, 1997.
18. Barktova, J., Lukas, J., Muller, H., Lutzhoft, D., Strauss, M., and Bartek, J. Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer, 57: 353-361, 1994.
19. Schauer, I. E., Siriwardans, S., Langan, T. A., and Sclafani, R. A. Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc. Natl. Acad. Sci. USA, 91: 7827-7831, 1994.
20. Jiang, W., Kahn, S. M., Zhou, P., Zhang, Y-J., Cacace, A. M., Infante, A. S., Doi, S., Santella, R. M., and Weinstein, I. B. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene, 8: 3447-3457, 1993.
21. Hinds, P. W., Dowdy, S. F., Eaton, E. N., Arnold, A., and Weinberg, R. A. Function of a human cyclin gene as an oncogene. Proc. Natl. Acad. Sci. USA, 91: 709-713, 1994.
22. Lovec, H., Sewing, A., Lucibello, F. C., Muller, R., and Moroy, T. Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene, 9: 323-326, 1994.
23. Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., and Schmidt, E. V. Mammary hyperplasia and carcinoma in MMTV-cyclin Dl transgenic mice. Nature (Lond.), 369: 669-671, 1994.
24. Lovec, H., Grzeschiczek, A., Kowalski, M. B., and Moroy, T. Cyclin D1/bc1-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J., 13: 3487-3495, 1994.
25. Bodrug, S. E., Warner, B. J., Bath, M. L., Lindeman, G. J., Harris, A. W., and Adams, J. M. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J., 13: 2124-2130, 1994.
26. Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. T., and Weinberg, R. A. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell, 82: 621-630, 1995.
27. Zhou, P., Jiang, W., Zhang, Y-J., Kahn, S. M., Schieren, I., Santella, R. M., and Weinstein, I. B. Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene, 11: 571-580, 1995.
28. Arber, N., Doki, Y., Han, E. K-H., Sgambato A., Zhou, P., Kim, N., Delohery, T., Klein, M. G., Holt, P. R., and Weinstein, I. B. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res., 57: 1569-1574, 1997.
29. Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tlsty, T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70: 923-935, 1992.
30. Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., and Wahl, G. M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70: 937-948, 1992.
31. Zhou, P., Jiang, W., Weghorst, C. M., and Weinstein, I. B. Overexpression of cyclin D1 enhances gene amplification. Cancer Res., 56: 36-39, 1996.
32. Kip1 protein in human esophageal cancer cell lines that overexpress cyclin D1. Carcinogenesis (Lond.), 18: 1139-1148, 1997.
33. Han, E. K-H., Begemann, M., Sgambato, A., Soh, J-W., Xing, W-Q., and Weinstein, I. B. Increased expression of cyclin D1 in a murine mammary epithelial cell line inhibits growth and enhances apoptosis. Cell Growth Differ., 7: 669-710, 1996.
34. Kip1. Cancer Res., 56: 1389-1399, 1996.
35. KIP1 expression. Cell Growth Differ., 8: 393-405, 1997.
36. Kip1 in human breast cancers. Clin. Cancer Res., 3: 1879-1887, 1997.
37. Kip1 in multistage colorectal carcinogenesis. Cancer Res., in press, 1997.
38. KIP1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 3: 222-225, 1997.
39. KIP1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227-230, 1997.
40. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Jessup, J. M., and Pagano, M. Increased proteosome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med., 3: 231-234, 1997.
41. WAF1/CIP1 in human brain tumors. Oncogene, 11: 2021-2028, 1995.
42. Marchetti, A., Doglioni, C., Barbareschi, M., Buttitta, F., Pellegrini, S., Bertacca, G., Chella, A., Merlo, G., Angeletti, C. A., Palma, P. D., and Bevilacqua, G. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene, 12: 1319-1324, 1996.
43. WAF1/CIP1 in normal, hyperplastic, and neoplastic uterine tissues. Hum. Pathol., 28: 60-66, 1997.
44. WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br. J. Cancer, 74: 208-215, 1996.
45. Himaya, H., Iavarone, A., LaBaer, J., and Reeves, S. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. Oncogene, 14: 2533-2542, 1997.
46. Anderson, M. J., Casey, G., Fasching, C. L., and Stranbridge, E. J. Evidence that wild-type TP53, and not genes on either chromosome I or II, controls the tumorigenic phenotype of the human fibrosarcoma HT1080. Genes Chromosomes Cancer, 9: 266-281, 1994.
47. Li, J., Hu, S-X., Perng, G-S., Zhou, Y., Xu, K., Zhang, C., Seigne, J., Benedict, W. F., and Xu, H-J. Expression of the retinoblastoma (RB) tumor suppressor gene inhibits tumor cell invasion in vitro. Oncogene, 13: 2379-2386, 1996.
48. Muller, H., Lukas, J., Schneider, A., Warthoe, P., Bartek, J., Eilers, M., and Strauss, M. Cyclin D1 expression is regulated by the retinoblastoma protein. Proc. Natl. Acad. Sci. USA, 91: 2945-2949, 1994.
49. Li, Y., Nichols, M. A., Shay, J. W., and Xiong, Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res., 54: 6078-6082, 1994.
50. Haput, Y., Maya, R., Kazaz, A., and Oren, M. Mdm2 promotes the rapid degradation of p53. Nature (Lond.), 387: 296-299, 1997.
51. Kubbutat, M. H. G., Jones, S. N., and Vousden, K. H. Regulation of p53 stability by Mdm2. Nature (Lond.), 387: 299-303, 1997.